UNSPSC 51313206: Pimethixene

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T46J20J26F, chemically known as piperidine, 1-methyl-4-thioxanthen-9-ylidene- but generally known as pimethixene, which bears US NIH Compound Identifier 4822. European Medicines Agency schedules Pimethixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09840MIG. The term PIMETHIXENE is an International Non-Proprietary Name.

UNSPSC 51313206 Pimethixene is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though recent activity shows the code applied to a broader range of pharmaceutical and related health-supply acquisitions than the code name alone suggests. State and local governments buying under this code procure naloxone and drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and related therapeutic pharmacy services to support public health initiatives, emergency response programs, and state employee health plans. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances administering contracts on behalf of participating state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other members).

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County posted IFB 60459723LAS on June 30, 2026, with a July 26, 2023 response deadline, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, a market-intelligence phase preceding formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awarded vendors effective July 1, 2026. The MMCAP procurement weights price competitiveness at 75 percent and requires vendors to maintain relationships with at least two of the three designated wholesalers, comply with cGMP and Drug Supply Chain Security Act standards, and carry commercial general liability of $5,000,000 per occurrence.